The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
Commentary|Articles|December 3, 2025
Lower-Intensity Regimens and CAR T-Cell Advances Drive Progress in AML and ALL at ASH 2025
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Hematology experts share the AML and ALL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.
Advertisement
Advertisement
Research advances with azacitidine (Vidaza)/venetoclax (Venclexta)–based regimens in acute myeloid leukemia (AML) and CAR T-cell therapies in acute lymphoblastic leukemia (ALL) are set to steal the show during the
Related to this article
The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive posttransplant lymphoproliferative disease.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.
The European Commission approved pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, irrespective of cisplatin eligibility.
Thoracic oncologists weigh how TROP2-directed antibody-drug conjugates fit into sequencing and combination strategies for EGFR-mutated NSCLC.
Patients with pancreatic cancer experience measurable changes in body composition years before diagnosis that differ from those seen in similar individuals without cancer.
Advertisement
Advertisement